We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Apple Watch App Identifies Irregular Heart Rhythms

By HospiMedica International staff writers
Posted on 29 Jan 2018
A first-of-its-kind research study will use the Apple Watch’s heart rate sensor to collect data on irregular heart rhythms and notify users who may be experiencing atrial fibrillation (AF).

The Apple (Cupertino, CA, USA) Heart Study app, launched in partnership with Stanford University School of Medicine (CA, USA), is available for download on the Apple App Store to holders of an Apple Watch Series 1 or later, and who are 22 years or older. More...
To calculate heart rate and rhythm, Apple Watch’s sensor uses green light emitting diode (LED) lights flashing hundreds of times per second and light-sensitive photodiodes to detect the amount of blood flowing through the wrist.

The sensor’s unique optical design gathers signals from four distinct points on the wrist, and when combined with powerful software algorithms, the Apple Watch can isolate actual heart rhythms from other incidental noise. As part of the study, if an irregular heart rhythm is identified, participants will receive a notification on their Apple Watch and iPhone, together with a free consultation with a study doctor and an electrocardiogram (ECG) patch for additional monitoring.

“Every week we receive incredible customer letters about how Apple Watch has affected their lives, including learning that they have atrial fibrillation. These stories inspire us, and we're determined to do more to help people understand their health,” said Jeff Williams, COO of Apple. “Working alongside the medical community, not only can we inform people of certain health conditions, we also hope to advance discoveries in heart science.”

“Through the Apple Heart Study, Stanford Medicine faculty will explore how technology like Apple Watch’s heart rate sensor can help usher in a new era of proactive health care central to our Precision Health approach,” said Lloyd Minor, MD, dean of Stanford University School of Medicine. “We’re excited to work with Apple on this breakthrough heart study.”

AF occurs when the heart's two upper chambers beat erratically. In one form, paroxysmal AF, patients have bouts of erratic beats that begin spontaneously and usually last less than a week. AAD can control the heart rhythm and symptoms of AF, but many patients do not respond well. AF can lead to serious adverse events such as thrombi traveling from the heart to obstruct arteries supplying the brain, causing stroke, or other parts of the body causing tissue damage.

Related Links:
Apple
Stanford University School of Medicine

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Half Apron
Demi
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.